The CDC recommended that children ages 5 to 11 with immune system deficiencies receive a booster dose of Pfizer-BioNTech.
Photo: JACK GUEZ / AFP / Getty Images
The U.S. Centers for Disease Control (CDC) this Tuesday reduced the minimum time from six to five months time between receiving the second dose of the Pfizer-BioNTech vaccine and the third.
On the other hand, the minimum waiting period for those who received the Moderna vaccine (6 months until the booster dose) and Johnson & Johnson (2 months until the booster dose) was not modified.
In addition, the CDC recommended that children ages 5 to 11 with immune deficiencies receive a booster dose of Pfizer-BioNTech (the only one approved for this age) 28 days after being inoculated with the second dose.
“Today’s recommendations guarantee that people will be able to receive a booster dose to protect themselves against omicron and the increase in cases across the country,” CDC Director Rochelle Walensky said in a statement.
The CDC is thus following the indications already pointed out on Monday by the United States Food and Drug Administration (FDA, for its acronym in English).
In addition, on Monday the FDA approved the use of the Pfizer / BioNTech covid-19 booster vaccine for children between the ages of 12 and 15, believing that the benefits outweigh the risks.
“The benefits of a booster dose of Pfizer / BioNTech to provide continued protection against COVID-19 and the possible associated consequences of hospitalization and death outweigh the potential risks in individuals between the ages of 12 and 15,” stated the FDA in a statement.
The United States registered more than a million new cases of covid-19 yesterday, the record since the start of the pandemic, according to the independent count carried out by Johns Hopkins University.
Specifically, 1,082,549 new cases were reported, although the figure may be distorted due to the delay in the delivery of data for the weekend and the end of the year party.
You may also be interested in:
–COVID-19 cases on Rikers Island exceed record 37% positivity rate
–IHU: They discover a new variant of Covid-19 with more mutations than Ómicron
–Ómicron has led many US companies to delay their return to the office